Assignee
JANUX THERAPEUTICS INC
US·4 granted patents·28 pending applications·8 citations·filing 2018–2025
Top patents by PatentIndex Score
32 records- 0194US11512113B2Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Granted Nov 29, 2022·7 cites·25 claims
- 0288US12161724B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·1 cites·21 claims
- 0381US2026001963A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0480US12433953B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2024·Granted Oct 7, 2025·0 cites·31 claims
- 0579US2026014267A1Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0678US2024376226A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0778US2025019403A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0872US2023348618A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0971US2023147782A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1070US11555078B2Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Granted Jan 17, 2023·0 cites·26 claims
- 1170US2023270854A1Modified antibodiesJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1262US2023220105A1Tumor activated t cell engagers and methods of use thereofJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1362US2023220109A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1462US2026049140A1Tumor activated antibodies targeting cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1561US2023357429A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1661US2023357447A1Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1760US2025154278A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1860US2024059790A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1959US2026049137A1Optimized antibodies targeting cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2058US2024254241A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2158US2018339043A1Modified antibodiesJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2256US2024034814A1Half-life extending compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2355US2024043536A1Peptide compositions and methods for anti-cd3 binding domainsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2455US2024034806A1Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2554US2023406955A1Antibodies targeting her2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2654US2021115106A1Modified t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2754US2024092931A1Antibodies targeting trop2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2854US2024043565A1Antibodies targeting psma and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2954US2023406937A1Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3054US2020385440A1Modified bispecific t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3151US2025250339A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3249US2025297017A1Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when JANUX THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →